MedPath

Alflutinib

Generic Name
Alflutinib
Drug Type
Small Molecule
Chemical Formula
C28H31F3N8O2
CAS Number
1869057-83-9
Unique Ingredient Identifier
A49A7A5YN4

Overview

Alflutinib is under investigation in clinical trial NCT03452592 (Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients With T790M).

Background

Alflutinib is under investigation in clinical trial NCT03452592 (Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients With T790M).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC
Phase 2
Not yet recruiting
Posted: 2022/01/26
Sponsor:
The First Affiliated...
ID:NCT05209256
Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）
Phase 3
Active, not recruiting
Posted: 2018/12/27
Sponsor:
Allist Pharmaceutica...
ID:NCT03787992
Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790M
Phase 2
Terminated
Posted: 2018/03/02
Sponsor:
Allist Pharmaceutica...
ID:NCT03452592
AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations
Not Applicable
Terminated
Posted: 2017/04/25
Sponsor:
Allist Pharmaceutica...
ID:NCT03127449
Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer
Phase 1
Terminated
Posted: 2016/11/25
Sponsor:
Allist Pharmaceutica...
ID:NCT02973763

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy